Oxford BioDynamics Plc (AIM:OBD)

Revenue by Segment

Financials in millions GBP. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
Sales of Proprietary Products and Biomarker Research and Development	1.10M	636.00K	510.00K	154.00K	341.00K
Sales of Proprietary Products and Biomarker Research and Development Growth	72.17%	24.71%	231.17%	-54.84%	-25.22%
Total	1.10M	636.00K	510.00K	154.00K	341.00K
Total Growth	72.17%	24.71%	231.17%	-54.84%	-25.22%

Revenue by Geography

Financials in millions GBP. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
United States of America (USA)	958.00K	459.00K	388.00K	107.00K	341.00K
United States of America (USA) Growth	108.71%	18.30%	262.62%	-68.62%	-9.79%
Rest of The World	137.00K	177.00K	122.00K	47.00K	-
Rest of The World Growth	-22.60%	45.08%	159.57%	-	-
Total	1.10M	636.00K	510.00K	154.00K	341.00K
Total Growth	72.17%	24.71%	231.17%	-54.84%	-25.22%

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error